Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Clinical Applications Could Shape FTSE 250 Life Sciences Stock Oxford Nanopore (LSE:ONT)

Clinical applications could shape Oxford Nanopore (LSE:ONT) because moving its DNA and RNA sequencing technology from the research bench into hospitals and diagnostics is the company's clearest route to faster growth and, eventually, profit. Clinical work commands higher volumes and more repeatableDemandthan one-off research …

Ankur Sharma | 18 September 2026

CVS Group Eases Back: Veterinary Sector Regulation Still Looming

CVS Group PLC (LSE:CVSG) shares fell -0.15% today, based on the supplied market data. The shares last traded at 1316.00p, down -2.00 on the day.

Divya Sood | 18 September 2026

Genus Falls Back: Does the Animal Genetics Leader Still Have Room to Grow?

Genus PLC shares fell -1.50% today, based on the supplied market data. The shares last traded at 2102.00p, down -32.00 on the day.

Divya Sood | 18 September 2026

What Would Convincing Clinical Evidence Mean for FTSE AIM’s Scancell (LSE:SCLP)?

Scancell Holdings, listed on London’s AIM, develops off-the-shelf cancer immunotherapies, often described as therapeutic cancer vaccines, designed to stimulate the immune system to attack tumours. It works across platforms including its DNA-based ImmunoBody technology, behind its lead melanoma candidate iSCIB1+, and its Moditope platform, …

Ankur Sharma | 17 September 2026

How Could FTSE AIM’s AOTI (LSE:AOTI) Turn Wound-Care Technology Into Wider Adoption?

AOTI, listed on London’s AIM, develops and sells topical wound oxygen therapy, marketed as TWO2, an intermittent oxygen treatment delivered to patients at home for chronic wounds such as diabetic foot ulcers. By applying oxygen directly to the wound in cycles, the therapy aims …

Ankur Sharma | 17 September 2026

Why Precision Medicine Could Create a Bigger Market for FTSE AIM’s Diaceutics (LSE:DXRX)

Diaceutics, listed on London’s AIM, providesData Analyticsand advisory services to pharmaceutical companies, helping them commercialise precision-medicine therapies. Many modern drugs work only for patients with specific biomarkers, so identifying and testing those patients is essential. Through its DXRX platform, Diaceutics gathers and analyses diagnostic …

Ankur Sharma | 17 September 2026

Why Did Spire Healthcare Group PLC LSE:SPI Fall 0.20% Amid a softer tone across London-listed hospital and clinical services shares?

Spire Healthcare Group PLC — LSE:SPI closed 0.20% lower on17 September 2026, with the shares at 245.50p after a decline of 0.50p on the day.

Ishan Mudgal | 17 September 2026

Why Did Genus PLC LSE:GNS Rise 0.37% Amid a firmer tone across London-listed animal genetics and life sciences shares?

Genus PLC — LSE:GNS closed 0.37% higher on17 September 2026, with the shares at 2,158.00p after a gain of 8.00p on the day.

Ishan Mudgal | 17 September 2026

Why Did Oxford Nanopore Technologies PLC LSE:ONT Rise 0.59% Amid a firmer tone across London-listed life sciences and diagnostics shares?

Oxford Nanopore Technologies PLC — LSE:ONT closed 0.59% higher on17 September 2026, with the shares at 162.26p after a gain of 0.96p on the day.

Ishan Mudgal | 17 September 2026

What Could Demand for Injectable Medicines Mean for FTSE 250 Drugmaker Hikma Pharmaceuticals (LSE:HIK)?

Half-year figures published on 6 August 2026 revealed a group leaning on its other divisions while injectables paused for breath.

Ankur Sharma | 17 September 2026
Support

Hi! How can we help you today?

Loading…